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Abstract
The development of CRISPR depends, in part, on the patents—past, present, and future—covering it. As for the
past, the origins of the CRISPR patent landscape predate its use as a gene editing technology. Fundamental pat-
ents covering CRISPR-Cas9 as a genomic editing system did not first arise until 2012; they sparked the now ca-
nonical dispute between the University of California and the Broad Institute. The present dispute has not stopped
widespread licensing of critical patents, however, bringing with it an explosion of research from both academic
and commercial sectors. Whether this broad availability will persist in the future remains uncertain. The ease and
reliability of CRISPR threatens many future patents as being ‘‘obvious.’’ Nor is it clear how academic scientists and
technology transfer offices will respond to the patent dispute. Like the technology itself, the future of the CRISPR
patent landscape depends on researchers and their institutions.
Introduction
Besides revolutionizing molecular biology, CRISPR* has
intensified public discourse on science and science pol-
icy. For better or worse, this has also included a focus
on the contentious and rapidly burgeoning patent estate
covering CRISPR and its various applications. News sto-
ries describing CRISPR as a groundbreaking gene editing
technology number in the thousands; hundreds of those,
surprisingly, discuss the variety of patent issues involved.
The inaugural issue of The CRISPR Journal presents
an excellent opportunity to take stock of the CRISPR pat-
ent landscape as a whole. As our new readers—namely,
academic researchers and industry scientists—find them-
selves interacting with the patent system more and more,
it becomes increasingly important for them to understand
the major patent issues in this area. This shouldn’t fail to
include attorneys and social scientists who see the
CRISPR patent estate as a case study of technological
adoption and property rights. And this inaugural issue
also provides the public—given its outsized interest in
the technology—with a window for observing the history
of the CRISPR patent estate. To that end, this Commen-
tary provides not only a snapshot of the CRISPR patent
dispute, but also an assessment of where the patents cov-
ering the technology have been, where they are now, and
how they will be extended in the future: the past, present,
and future landscape of CRISPR patents.
Past
The CRISPR patent estate—much like the invention of
CRISPR itself—has been cloaked in its own mythology,
an ur-combat myth between Jennifer Doudna (Howard
Hughes Medical Institute (HHMI)/University of Califor-
nia, Berkeley [UC]) and Emmanuelle Charpentier (then
of the University of Umëa, Sweden), on one side, and
Feng Zhang (Broad Institute) on the other. The historical
record of CRISPR’s origins in the patent office, however,
is much more prosaic.
The first U.S. patent to mention CRISPR in any form is
likely U.S. Patent No. 7,919,277, naming W. Michael
Russell, Rodolphe Barrangou,{ and Philippe Horvath as
inventors, and originally filed April 28, 2004—a full 8
years before patents claiming CRISPR as a gene editing
technology. This ’277 patent, assigned to Danisco A/S,
the Danish food chemistry company, modestly claimed a
method of sequencing certain CRISPR regions in a sample
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to detect variants of Lactobacillus acidophilus, the bacterial
workhorse of industrial yogurt production. Barrangou and
his collaborators filed several more CRISPR-related patent
applications around this time, for similarly narrow applica-
tions encompassing strain typing, phage resistance, and
various uses in bacteria.1–3 Several more CRISPR patents
followed soon after, including a patent claiming the use
of CRISPR guide sequences to inactivate, through cleav-
age, microbial DNA—U.S. Patent No. 8,546,553, from
the Terns’ lab at University of Georgia, filed on July 25,
2008. Notably, Francisco Mojica—the Spanish microbiol-
ogist who was the first researcher to catalog CRISPR se-
quences across prokaryotic domains (see ‘‘Crazy About
CRISPR: An Interview with Francisco Mojica’’ in this
issue)—is not listed as an inventor on any patent applica-
tions, CRISPR or otherwise, filed around this time. The or-
igins of the CRISPR patent estate, far from being forged in
combat, were gently cultured in distant tuns.
It was not until 2012, rather, that U.S. patent applica-
tions claiming the use of CRISPR as a gene editing sys-
tem began to appear—immediately prior to the seminal
papers from the Virginijus Šikšnys lab (Vilnius Univer-
sity, Lithuania)4 and the Doudna and Charpentier collab-
oration.5 These patent applications from Šikšnys (filed
March 20, 2012),6 Doudna and Charpentier (filed May
25, 2012),7 and Zhang (filed December 12, 2012)8 all
claimed some variation of the engineerable, single-guide
RNA (sgRNA), Type II CRISPR system well-known
today, focusing on the promising Cas9 endonuclease.
Despite this sequence of patent filings, Zhang’s patent ap-
plication was the first to be granted by the U.S. Patent and
Trademark Office (PTO), owing to the Broad’s attorneys
use of a strategically risky ‘‘fast tracking’’ procedure (for-
mally known as a ‘‘Petition to Make Special,’’) and, argu-
ably, the limiting of the application’s claims to eukaryotic
uses.9 This established the now famous conflict between
UC and the Broad Institute: Zhang’s patent was granted
first, even though, on the papers filed with the PTO,
Doudna and Charpentier appeared to be both prior inven-
tors and prior applicants.3
Beginning in January 2016, the PTO attempted to re-
solve this conflict through a particular type of procedure,
an interference proceeding, at the suggestion of UC’s at-
torneys.10 Interference proceedings operate, essentially,
as trials within the PTO to determine the scope and prior-
ity of two sets of conflicting patent applications. UC’s at-
torneys argued that the Doudna patent application was
the first to disclose the use of a sgRNA CRISPR-Cas9
gene-editing system in any cell type—prokarya, archaea,
or eukarya.11 The Broad’s attorneys, by contrast, argued
that Zhang’s application was the first to demonstrate how
the system worked specifically in eukaryotes, a sepa-
rately patentable invention by their count.11 After a
year’s worth of filings by each side’s attorneys, a panel
of Administrative Patent Judges heard oral arguments
in a 40-minute hearing—held on a rainy Tuesday, De-
cember 6, 2016, in Hearing Room A at the PTO’s head-
quarters in Alexandria, Virginia. Neither Doudna,
Charpentier, Zhang, nor Šikšnys were present (Fig. 1).
On February 15, 2017, the PTO sided with the
Broad’s attorneys that Zhang’s patent application cover-
ing eukaryotic applications of the technology was a sep-
arately patentable invention.11 As a result, the two sets
of applications—Doudna and Charpentier’s and Zhang’s—
did not ‘‘interfere in fact’’ with one another. But as
with many legal judgments, there is always the possibility
of appeal—an avenue UC employed shortly after the
PTO’s decision.12 We currently await the outcome of
the appeal—likely to arrive in mid-2018—and the close
of one chapter of the CRISPR patent estate’s past.
Present
If the past of the CRISPR patent estate was one of narrow
conflict, the present is one of widespread cooperation.
CRISPR patents from both UC and the Broad Institute
have been widely licensed to academic and industrial de-
velopers alike. UC, the Broad Institute, and more than
700 other institutions have all agreed to make their
CRISPR constructs—and intellectual property—widely
available through AddGene, a nonprofit repository and
patent licensor of CRISPR technologies for academic or-
ganizations.13 Despite the potential for conflict among
the many institutions involved, academic CRISPR re-
search has accelerated.
Academic institutions have also engaged in broad
cross-licensing agreements. With respect to UC’s
foundational CRISPR patent application, for example,
Doudna, Charpentier, and their spinoffs—Caribou Bio-
sciences and CRISPR Therapeutics, respectively—orig-
inally had their own separate interests to the patent, a
point of some contention during the interference trial.
But shortly after the interference argument in 2016, all
parties concerned announced a global cross-licensing
agreement, putting to rest any potential conflict among
them.14
The Broad Institute, too, recently announced a signif-
icant cross-licensing effort for its CRISPR patents for ag-
ricultural applications. The agreement brings together the
Broad, Monsanto, DuPont Pioneer, Caribou Biosciences,
ERS Genomics, and Vilnius University, apparently pool-
ing the patent interests held by Doudna, Charpentier,
Zhang, and Šikšnys.15 Some of the agreement is per-
haps a clever effort in gamesmanship to resolve the dis-




























































agricultural users of CRISPR-Cas9 can reap its social
benefits.
Commercial human therapeutic research proceeds
apace, too, although with more constraints. Both UC and
the Broad Institute have granted surrogate companies—
companies with dual responsibilities to develop and
license out CRISPR technologies—broad exclusive
licenses to their patent interests, Caribou Biosciences,
in UC’s case, and Editas Medicine, in Broad’s.16 These
exclusive licenses are not specific to any gene in the ge-
nome or even a human disease indication. As such, they
extend far often beyond what the surrogate can develop
itself. To that end, these surrogate licenses threaten to
bottleneck commercial research if smaller developers
cannot obtain the rights they need from the surrogates.16
Yet, these uncertainties surrounding licensing have not
stopped commercial companies from announcing ambi-
tious human pilot studies and future clinical trials.17
Beyond the license arrangements for these founda-
tional patents, many newer patent CRISPR applications
are being filed. To date, the PTO has granted more than
450 patents pertaining to CRISPR in some form, many
to institutions that have no relationship with either UC
or the Broad Institute.18 And this is likely just the tip of
the iceberg: the PTO keeps patent applications secret
until 18 months after they are filed, providing a current
snapshot of patent applications only before mid-2016.
In contrast to the past, the CRISPR landscape of the pres-
ent is enormously varied, with more specific claims scat-
tered among the hands of many.
Future
The CRISPR patent landscape of the future is uncertain—
uncertain due to the power of the technology, the senti-
ment of researchers and their institutions, and the quirks
of patent law. In particular, the power of CRISPR raises
difficult legal questions about what constitutes a signifi-
cant invention. All patents must be new, useful, and ‘‘non-
obvious’’—that is, more than a mere trivial application of
prior research. Now that the power of CRISPR as a
genome-editing technology has been elucidated, is any fu-
ture application of it nonobvious? The interference deci-
sion between UC and the Broad Institute rested, in part,
on the finding that, in 2012, there was no ‘‘reasonable ex-
pectation of success’’ in developing a Type II CRISPR-
Cas9 system in eukaryotes.11 Whether that was indeed
FIG. 1. ‘‘May it please the court’’: a courtroom artist captures legal arguments during a hearing at the PTO
headquarters in Alexandria, Virginia, in December 2016. Courtesy: Dana Verkouteren.



























































true in 2012 remains open for debate, but it is certainly no
longer the case. Today, it seems that there is a reasonable
expectation of success in using CRISPR as a genome-
editing tool for any system or cell type, and that, at a
minimum, is at least obvious to try using CRISPR to ac-
complish these goals—two standards in patent law that
strongly counsel against the patenting of follow-on in-
ventions. CRISPR-based genome editing, in other
words, is becoming a more predictable technology.
Future patents applications covering CRISPR should
consequently be more difficult to obtain.
This assumes, of course, that CRISPR scientists will at-
tempt to patent their inventions widely—a social event
that may not come to pass. The patent dispute between
UC and the Broad Institute has been met with disgust
by some scientists. Michael Eisen, an HHMI/UC Berkeley
colleague of Doudna’s and ever the firebrand, condemned
patents writ large as ‘‘destroying the soul of academic
science.’’19 Eisen’s views surely cannot be unique. On a
larger scale, hundreds of researchers have freely deposited
their CRISPR constructs—subject to broad, academic-
friendly license agreements—with AddGene.13 And
some institutions, notably the Montreal Neurological
Institute, have sworn off patents altogether.20 CRISPR
still has the glint of lucre, and many scientists are likely
to rush off to the gold mine, pickaxe in hand. But for oth-
ers, the future of the CRISPR patent landscape may very
well be less populated than its recent past.
The future of the CRISPR landscape will also depend,
in part, on extending the recent shift toward cross-
licensing. Eventually, the interference proceeding be-
tween UC and the Broad Institute will be resolved—either
by agreement or by the heavy hand of a court judgment.
So will ongoing proceedings regarding seminal patent ap-
plications in Europe, China, and elsewhere.21 Researchers
and industry can hope that the resolution of these past con-
flicts will further drive cooperative patent licensing
among the major players, rather than a retrenchment of
exclusive rights and patent thickets.
And yet, the future of the CRISPR patent landscape—
like the terra nova of a new planet—may be altogether
unseen. New applications for CRISPR—some wholly out-
side the context of genome editing—continue to arise
at a rapid pace. RNA editing, astronomically powerful
nucleic acid detection, and gene drives have all been de-
veloped since the invention of the single guide RNA
in 2012, and all are expected to be patented.22–24 This
includes the continual discovery of new nucleases, such
as CasX, CasY, and Cas13a, that belong to new types
and subtypes of CRISPR-Cas systems.25 The future of
CRISPR, and its patents, lies in researchers’ discoveries
and imaginations, subject to their institutions’ graces.
Conclusion
Although barely 5 years old, CRISPR as a genome editing
system has transformed both laboratory practice and clin-
ical aspiration. Whether it will fulfill these lofty promises
lies in the hands of its practitioners and their interaction
with the U.S. and other patent regimes—choices, ulti-
mately, between conflict and cooperation. Patents can
indeed serve as useful tools to develop a technology com-
mercially. But like all tools, they wield no power apart
from their users. The future of CRISPR patent landscape—
like the future of CRISPR itself—depends on the stew-
ardship of its researchers and their institutions.
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